CNPY4

Summary

CNPY4 (canopy FGF signaling regulator 4, HGNC:28631) is a protein-coding gene on chromosome 7q22.1, encoding Protein canopy homolog 4 (Q8N129). Plays a role in the regulation of the cell surface expression of TLR4.

Predicted to enable signaling receptor binding activity. Involved in positive regulation of protein localization to plasma membrane. Predicted to be located in extracellular region.

Source: NCBI Gene 245812 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 49 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_152755

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28631
Approved symbol	CNPY4
Name	canopy FGF signaling regulator 4
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC40499, PRAT4B
Ensembl gene	ENSG00000166997
Ensembl biotype	protein_coding
OMIM	610047
Entrez	245812

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000262932, ENST00000462193, ENST00000470153, ENST00000480692, ENST00000483756, ENST00000907886, ENST00000907887, ENST00000919349, ENST00000970780, ENST00000970781, ENST00000970782

RefSeq mRNA: 1 — MANE Select: NM_152755 NM_152755

CCDS: CCDS34701

Canonical transcript exons

ENST00000262932 — 6 exons

Exon	Start	End
ENSE00001145024	100124725	100125508
ENSE00001145029	100119634	100119862
ENSE00003519590	100122481	100122577
ENSE00003566223	100122784	100122906
ENSE00003647891	100122259	100122385
ENSE00003669600	100124514	100124631

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 95.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.8646 / max 233.8291, expressed in 1760 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79927	17.0466	1756
79928	0.4444	215
79929	0.3735	199

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	95.20	gold quality
diaphragm	UBERON:0001103	90.85	gold quality
type B pancreatic cell	CL:0000169	90.82	silver quality
granulocyte	CL:0000094	90.28	gold quality
olfactory bulb	UBERON:0002264	90.04	gold quality
descending thoracic aorta	UBERON:0002345	89.99	gold quality
smooth muscle tissue	UBERON:0001135	89.88	gold quality
right ovary	UBERON:0002118	89.82	gold quality
endocervix	UBERON:0000458	89.52	gold quality
ventricular zone	UBERON:0003053	89.12	gold quality
right adrenal gland cortex	UBERON:0035827	88.96	gold quality
left ovary	UBERON:0002119	88.88	gold quality
body of uterus	UBERON:0009853	88.79	gold quality
thoracic aorta	UBERON:0001515	88.69	gold quality
calcaneal tendon	UBERON:0003701	88.63	gold quality
ascending aorta	UBERON:0001496	88.62	gold quality
adenohypophysis	UBERON:0002196	88.58	gold quality
right adrenal gland	UBERON:0001233	88.56	gold quality
apex of heart	UBERON:0002098	88.40	gold quality
gall bladder	UBERON:0002110	88.30	gold quality
vena cava	UBERON:0004087	88.18	gold quality
ectocervix	UBERON:0012249	88.14	gold quality
pituitary gland	UBERON:0000007	87.80	gold quality
left adrenal gland	UBERON:0001234	87.79	gold quality
adrenal cortex	UBERON:0001235	87.53	gold quality
left adrenal gland cortex	UBERON:0035825	87.39	gold quality
left uterine tube	UBERON:0001303	87.27	gold quality
left coronary artery	UBERON:0001626	86.93	gold quality
adrenal gland	UBERON:0002369	86.76	gold quality
tongue squamous epithelium	UBERON:0006919	86.73	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting CNPY4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-5690	99.25	67.58	1012
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-655-5P	98.74	65.93	888

Literature-anchored findings (GeneRIF, showing 2)

• A PRotein Associated with Tlr4 (PRAT4B), regulates cell surface expression of TLR4. PRAT4B has a signal peptide followed by a mature peptide. PRAT4B is associated with the hypoglycosylated, immature form of TLR4 but not with MD-2 or TLR2. (PMID:16338228)
• a mechanism for the differential trafficking of TLR1 I602S variants, and highlight the distinct roles for PRAT4A and PRAT4B in the regulation of TLR1 surface expression. (PMID:22447933)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cnpy4	ENSDARG00000055797
mus_musculus	Cnpy4	ENSMUSG00000036968
rattus_norvegicus	Cnpy4	ENSRNOG00000027175
drosophila_melanogaster	CNPYb	FBGN0036847
caenorhabditis_elegans		WBGENE00007531

Paralogs (1): CNPY3 (ENSG00000137161)

Protein

Protein identifiers

Protein canopy homolog 4 — Q8N129 (reviewed: Q8N129)

All UniProt accessions (3): Q8N129, A0A0J9YXE1, A0A0J9YYJ0

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the regulation of the cell surface expression of TLR4.

Subunit / interactions. Interacts with TLR4.

Subcellular location. Secreted.

Similarity. Belongs to the canopy family.

RefSeq proteins (1): NP_689968* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021852	DUF3456	Domain

Pfam: PF11938

UniProt features (9 total): disulfide bond 3, compositionally biased region 2, signal peptide 1, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N129-F1	79.97	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 38–196, 41–184, 94–156

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 110 (showing top): BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, YY1_Q6, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, YY1_02, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, GOMF_SIGNALING_RECEPTOR_BINDING, GOBP_LOCALIZATION_WITHIN_MEMBRANE, GCCATNTTG_YY1_Q6, NUYTTEN_EZH2_TARGETS_DN, OSF2_Q6, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, GOBP_PROTEIN_LOCALIZATION_TO_PLASMA_MEMBRANE

GO Biological Process (1): positive regulation of protein localization to plasma membrane (GO:1903078)

GO Molecular Function (2): signaling receptor binding (GO:0005102), protein binding (GO:0005515)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein localization to plasma membrane	1
regulation of protein localization to plasma membrane	1
positive regulation of protein localization to cell periphery	1
positive regulation of protein localization to membrane	1
protein binding	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

266 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CNPY4	LY96	Q9Y6Y9	828
CNPY4	TLR4	O00206	746
CNPY4	CNPY2	Q9Y2B0	644
CNPY4	CNPY1	Q3B7I2	584
CNPY4	GML	Q99445	573
CNPY4	TLR2	O60603	491
CNPY4	HSP90B1	P14625	469
CNPY4	LRIG3	Q6UXM1	457
CNPY4	LRRC40	Q9H9A6	446
CNPY4	UNC93B1	Q9H1C4	419
CNPY4	SPMAP2	Q9P2T0	388
CNPY4	IL3	P08700	387
CNPY4	GLRX3	O76003	333
CNPY4	LRIG2	O94898	331
CNPY4	D6RI10	D6RI10	322

IntAct

33 interactions, top by confidence:

A	B	Type	Score
CHAD	CNPY4	psi-mi:“MI:0914”(association)	0.560
CNPY4	AIFM2	psi-mi:“MI:0915”(physical association)	0.560
CHAD	CNPY4	psi-mi:“MI:0915”(physical association)	0.560
LRIG1	LRIG2	psi-mi:“MI:0914”(association)	0.530
LRRTM4	AP3B1	psi-mi:“MI:0914”(association)	0.530
ISLR	BCKDK	psi-mi:“MI:0914”(association)	0.530
LRRTM2	GPC3	psi-mi:“MI:0914”(association)	0.530
KERA	FBXO21	psi-mi:“MI:0914”(association)	0.530
KERA	VWA8	psi-mi:“MI:0914”(association)	0.350
ISLR	DDX11L8	psi-mi:“MI:0914”(association)	0.350
PODN	LRP5	psi-mi:“MI:0914”(association)	0.350
LRRTM2	PTPRD	psi-mi:“MI:0914”(association)	0.350
ORF3	RNH1	psi-mi:“MI:0914”(association)	0.350
RXFP1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
LGR4	POLRMT	psi-mi:“MI:0914”(association)	0.350
LRRC17	ZZEF1	psi-mi:“MI:0914”(association)	0.350
ISM2	PEX1	psi-mi:“MI:0914”(association)	0.350
LRRTM3	ADCY9	psi-mi:“MI:0914”(association)	0.350
GP5	SLC19A2	psi-mi:“MI:0914”(association)	0.350
CLN5	ADGRL1	psi-mi:“MI:0914”(association)	0.350
PODN	HSPA5	psi-mi:“MI:0914”(association)	0.350
RXFP2	LIMK1	psi-mi:“MI:0914”(association)	0.350
ITIH6	CNPY4	psi-mi:“MI:0914”(association)	0.350
LYPD1	ADAM10	psi-mi:“MI:0914”(association)	0.350
VASN	DENND11	psi-mi:“MI:0914”(association)	0.350
AIFM2	CNPY4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (29): CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Two-hybrid), CNPY4 (Proximity Label-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS)

ESM2 similar proteins: A0A0L0P4F8, A3KNS2, A5GFQ5, A8XEA2, B2GUV7, B2W244, B4N0P7, C4QZ06, C4R7X8, C4R7X9, F2QQ67, F2QZ66, H3JU05, O17966, O60841, P04786, P06101, P07799, P08113, P11387, P14599, P35016, P41148, P41511, P93119, Q00313, Q04750, Q05D44, Q06BR2, Q07050, Q09261, Q0IF93, Q0P5N1, Q10651, Q27746, Q2L6K8, Q2L6L1, Q5HZV5, Q5RDE1, Q61712

Diamond homologs: A3KNS2, A5GFQ5, Q0P5N1, Q2L6K8, Q3SWX1, Q5HZV5, Q6GN40, Q8BQ47, Q8N129, Q9BT09, Q9DAU1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

985 predictions. Top by Δscore:

Variant	Effect	Δscore
7:100122227:A:AG	acceptor_gain	1.0000
7:100122228:C:G	acceptor_gain	1.0000
7:100122257:A:AG	acceptor_gain	1.0000
7:100122258:G:GG	acceptor_gain	1.0000
7:100122258:GT:G	acceptor_gain	1.0000
7:100122258:GTGT:G	acceptor_gain	1.0000
7:100122359:G:GT	donor_gain	1.0000
7:100122381:GTTTC:G	donor_gain	1.0000
7:100122382:TTTC:T	donor_gain	1.0000
7:100122384:TC:T	donor_gain	1.0000
7:100122386:G:GG	donor_gain	1.0000
7:100122568:A:G	donor_gain	1.0000
7:100124504:A:AG	acceptor_gain	1.0000
7:100124512:A:AG	acceptor_gain	1.0000
7:100124513:G:GG	acceptor_gain	1.0000
7:100124714:ATCC:A	acceptor_gain	1.0000
7:100124717:C:CA	acceptor_gain	1.0000
7:100124723:A:AG	acceptor_gain	1.0000
7:100124724:G:GG	acceptor_gain	1.0000
7:100124724:GC:G	acceptor_gain	1.0000
7:100124724:GCAT:G	acceptor_gain	1.0000
7:100122236:C:A	acceptor_gain	0.9900
7:100122254:A:AG	acceptor_gain	0.9900
7:100122255:C:G	acceptor_gain	0.9900
7:100122255:CCA:C	acceptor_loss	0.9900
7:100122256:CA:C	acceptor_loss	0.9900
7:100122257:AG:A	acceptor_loss	0.9900
7:100122257:AGT:A	acceptor_gain	0.9900
7:100122257:AGTGT:A	acceptor_gain	0.9900
7:100122258:GTG:G	acceptor_gain	0.9900

AlphaMissense

1617 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:100122867:G:C	W142C	0.997
7:100122867:G:T	W142C	0.997
7:100124558:G:C	W170C	0.996
7:100124558:G:T	W170C	0.996
7:100124598:T:A	C184S	0.996
7:100124599:G:C	C184S	0.996
7:100122896:T:C	L152P	0.995
7:100124556:T:A	W170R	0.994
7:100124556:T:C	W170R	0.994
7:100122283:T:C	L48P	0.993
7:100122570:A:C	Y112S	0.993
7:100122516:G:A	C94Y	0.992
7:100122809:T:C	L123P	0.992
7:100122865:T:A	W142R	0.992
7:100122865:T:C	W142R	0.992
7:100124514:T:C	C156R	0.992
7:100124559:T:G	Y171D	0.992
7:100124599:G:A	C184Y	0.992
7:100122261:T:A	C41S	0.991
7:100122262:G:C	C41S	0.991
7:100122515:T:A	C94S	0.991
7:100122516:G:C	C94S	0.991
7:100122569:T:G	Y112D	0.991
7:100122570:A:G	Y112C	0.991
7:100122790:A:C	S117R	0.991
7:100122792:T:A	S117R	0.991
7:100122792:T:G	S117R	0.991
7:100122818:T:C	L126P	0.991
7:100124514:T:A	C156S	0.991
7:100124515:G:C	C156S	0.991

dbSNP variants (sampled 300 via entrez): RS1000349935 (7:100122528 T>C), RS1000697193 (7:100124092 C>T), RS1000757558 (7:100118519 T>C), RS1001198871 (7:100120019 G>T), RS1001625842 (7:100121687 G>A,T), RS1001735567 (7:100125562 G>A), RS1001908091 (7:100121414 G>A), RS1001909220 (7:100120092 C>G), RS1002201203 (7:100121769 G>A,T), RS1002288845 (7:100125423 T>C), RS1002781849 (7:100124199 T>C), RS1003078013 (7:100123936 C>T), RS1003208020 (7:100122714 G>A,C), RS1004206264 (7:100123767 G>A), RS1004237513 (7:100123607 G>A)

Disease associations

OMIM: gene MIM:610047 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST005196_147	Coronary artery disease	2.000000e-06
GCST010002_259	Refractive error	3.000000e-16
GCST010275_5	Renal overload gout	6.000000e-07
GCST010702_48	Subcortical volume (MOSTest)	6.000000e-10
GCST010703_289	Brain morphology (MOSTest)	6.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1554973	Efficacy	3	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Inflammatory Bowel Diseases

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1554973	CNPY4, TLR4	3	2.50	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
Valproic Acid	affects expression, increases expression	2
Cadmium Chloride	decreases expression	2
Particulate Matter	increases abundance, affects cotreatment, decreases expression	2
GSK-J4	decreases expression	1
bisphenol A	affects cotreatment, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression, affects cotreatment	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Indomethacin	affects cotreatment, increases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms